First Ebola Vaccine Approved
The European Medicines Agency has approved the world’s first Ebola vaccine after it was administered to thousands of people in Africa.
The European Medicines Agency described licensing the vaccine as an essential step toward relieving the burden of this deadly disease. The Ebola vaccine was initially developed in Canada and is now marketed by Merck as Ervebo. More than 270,000 people in Africa have received it as officials try to stop Congo’s ongoing outbreak.
Since the Ebola outbreak was declared on August 2018, approximately 200,000 people have received doses of a vaccine made by Merck, which will continue to be used in the region.
First Ebola Vaccine Approved- The Much Needed Vaccine
A panel of the European drug regulator on Friday recommended approving Merck & Co’s vaccine for the deadly Ebola virus. According to official data, more than 3,030 people have been affected by the Ebola virus in this outbreak, one of the worst in history, and more than 1,990 have died.
The European Medicines Agency said its human medicines committee has recommended granting a conditional marketing authorization in the European Union for the vaccine, Ervebo, for individuals aged 18 years and older.
A second vaccine
made by Johnson & Johnson, which is not yet licensed, will soon be used in parts of Congo where Ebola is not actively spreading. The United Nations health agency, in a statement, said the second vaccine that is made by Johnson & Johnson, will be used from October 2019 in areas where Ebola is not actively spreading.First Ebola Vaccine Approved- Delay In Action
The question of whether the Johnson & Johnson experimental vaccine should be used was a matter of dispute between Congo’s former health minister and global health officials.
Meanwhile, The World Health Organization is convening a meeting to consider whether the epidemic in Congo should still be designated a global emergency.
